The purpose of this study is to test the safety of a study drug called KRT-232 (AMG 232) when used in combination with a standard treatment regimen for relapsed or refractory multiple myeloma. The standard treatment is with the drugs carfilzomib, lenalidomide, and dexamethasone (KRd).

The purpose of this study is to test the effectiveness of the drugs cabozantinib with nivolumab and ipilimumab in rare genitourinary (GU) cancers that have no standard treatment options.

Rhabdomyosarcoma (RMS) is a type of cancer that occurs in the soft tissues of the body like the muscles. This study will compare the safety and effect of adding vinorelbine to vincristine, dactinomycin, and cyclophosphamide (VAC) for the treatment of patients with high risk rhabdomyosarcoma (RMS). High risk refers to cancer that is likely to recur (come back) after treatment or spread to other parts of the body.

This study is for male and female children, adolescents, and young adults under the age of 25 who have been diagnosed with Chronic Myeloid Leukemia (CML) that is in the earliest phase known as the chronic phase. Chronic phase means that the level of disease is very low and is often called molecular remission.  To keep the CML at this low level, people typically take a type of drug called a tyrosine kinase inhibitor (TKI), such as imatinib, dasatinib, and nilotinib every day.
   

The purpose of this study is to test the safety of a drug called M3814 (peposertib) in combination with a specific type of radiation therapy (hypofractionated radiation) in patients with locally advanced pancreatic cancer. This study will test different doses of M3814 to see which dose is safer for people when combined with hypofractionated radiation.

This study is for people who have stage III colon cancer that has been treated with surgery but has spread to some of the lymph nodes, or who have stage II or stage III colon cancer that has been treated with surgery and has a higher risk of returning based on positive circulating tumor DNA (ctDNA) results. ctDNA is DNA that has been released from tumor cells into the bloodstream. This DNA can be measured using a blood test.
   

This study is open to men and women over the age of 18 who have Kaposi Sarcoma (KS). Kaposi Sarcoma is a cancer related to a viral infection, known as the Kaposi sarcoma-associated herpesvirus, or KSHV.

This study aims to learn more about whether the experimental medication osimertinib (TAGRISSO) is more effective than placebo in participants with Epidermal Growth Factor Receptor (EGFR) mutated stage IA2 or IA3 non small cell lung cancer (NSCLC) after complete surgical removal of the tumor. 

The purpose of this study is to evaluate the study drug, DS-8201a (also known as Enhertu or fam-trastuzumab deruxtecan-nxki) for advanced solid tumors. The study aims to see how DS-8201a affects the levels of certain proteins and immune cells in solid tumors, how well it works against cancer cells, and how safe and tolerable it is.

The United States Food and Drug Administration (FDA) has approved DS-8201a for the treatment of patients with advanced HER2-positive breast or gastric cancer.

This study is being done to determine if the study drug, Olaparib has an effect on urothelial carcinoma or other non-prostate genitourinary cancers in people with DNA-repair changes in their genes.

This study aims to determine if Olaparib is better or worse than the usual approach for urothelial cancer or other non-prostate genitourinary cancers. There is no standard of care for these cancers, but people who are not participating in a study are usually treated with single-drug taxane chemotherapies (e.g. paclitaxel, abraxane, docetaxel).